Current Progress and Future Developments of Antibody Drug Conjugates in Lung Cancer
Autor: | Yixiang ZHU, Zhijie WANG |
---|---|
Jazyk: | čínština |
Rok vydání: | 2022 |
Předmět: | |
Zdroj: | Chinese Journal of Lung Cancer, Vol 25, Iss 7, Pp 468-476 (2022) |
Druh dokumentu: | article |
ISSN: | 1009-3419 1999-6187 |
DOI: | 10.3779/j.issn.1009-3419.2022.102.22 |
Popis: | Antibody drug conjugates (ADCs) are a novel class of anti-cancer drugs, which combined the specificity of monoclonal antibodies with the cytotoxic palyload via the linkers. Many ADCs have not only verified impressive activity in a variety of cancers, including breast cancer and hematological system tumors, but also in lung cancer. The aim of this study was to provide informations for practice by summarizing the mechanism of action, clinical application and problems and challenges of ADCs. |
Databáze: | Directory of Open Access Journals |
Externí odkaz: |